Literature DB >> 31843982

A Runaway PRH/HHEX-Notch3-Positive Feedback Loop Drives Cholangiocarcinoma and Determines Response to CDK4/6 Inhibition.

Kevin Gaston1, Padma-Sheela Jayaraman2, Philip Kitchen3, Ka Ying Lee3, Danielle Clark4, Nikki Lau3, Jomnarong Lertsuwan5, Anyaporn Sawasdichai5, Jutamaad Satayavivad6, Sebastian Oltean7, Simon Afford8.   

Abstract

Aberrant Notch and Wnt signaling are known drivers of cholangiocarcinoma (CCA), but the underlying factors that initiate and maintain these pathways are not known. Here, we show that the proline-rich homeodomain protein/hematopoietically expressed homeobox (PRH/HHEX) transcription factor forms a positive transcriptional feedback loop with Notch3 that is critical in CCA. PRH/HHEX expression is elevated in CCA, and depletion of PRH reduces CCA tumor growth in a xenograft model. Overexpression of PRH in primary human biliary epithelial cells is sufficient to increase cell proliferation and produce an invasive phenotype. Interrogation of the gene networks regulated by PRH and Notch3 reveals that unlike Notch3, PRH directly activates canonical Wnt signaling. These data indicate that hyperactivation of Notch and Wnt signaling is independent of the underlying mutational landscape and has a common origin in dysregulation of PRH. Moreover, they suggest new therapeutic options based on the dependence of specific Wnt, Notch, and CDK4/6 inhibitors on PRH activity. SIGNIFICANCE: The PRH/HHEX transcription factor is an oncogenic driver in cholangiocarcinoma that confers sensitivity to CDK4/6 inhibitors. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31843982     DOI: 10.1158/0008-5472.CAN-19-0942

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

Review 1.  Cyclin-Dependent Kinase 4/6 Inhibitors: A Potential Breakthrough Therapy for Malignancies of Gastrointestinal Tract.

Authors:  Fuchun Zeng; Yubin Zhou; Theerawat Khowtanapanich; Charupong Saengboonmee
Journal:  In Vivo       Date:  2022 Jul-Aug       Impact factor: 2.406

2.  The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma.

Authors:  Orawan Suppramote; Sunisa Prasopporn; Satinee Aroonpruksakul; Ben Ponvilawan; Jiradej Makjaroen; Monthira Suntiparpluacha; Krittiya Korphaisarn; Komgrid Charngkaew; Rawisak Chanwat; Trairak Pisitkun; Seiji Okada; Somponnat Sampattavanich; Siwanon Jirawatnotai
Journal:  Front Oncol       Date:  2022-05-17       Impact factor: 5.738

3.  CK2-induced cooperation of HHEX with the YAP-TEAD4 complex promotes colorectal tumorigenesis.

Authors:  Yuegui Guo; Zhehui Zhu; Zhenyu Huang; Long Cui; Wei Yu; Wanjin Hong; Zhaocai Zhou; Peng Du; Chen-Ying Liu
Journal:  Nat Commun       Date:  2022-08-25       Impact factor: 17.694

Review 4.  Targeting protein kinase CK2 in the treatment of cholangiocarcinoma.

Authors:  Padma-Sheela Jayaraman; Kevin Gaston
Journal:  Explor Target Antitumor Ther       Date:  2021-10-31

5.  YAP Accelerates Notch-Driven Cholangiocarcinogenesis via mTORC1 in Mice.

Authors:  Xinjun Lu; Baogang Peng; Ge Chen; Mario G Pes; Silvia Ribback; Cindy Ament; Hongwei Xu; Rajesh Pal; Pedro M Rodrigues; Jesus M Banales; Matthias Evert; Diego F Calvisi; Xin Chen; Biao Fan; Jingxiao Wang
Journal:  Am J Pathol       Date:  2021-06-12       Impact factor: 5.770

6.  Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells.

Authors:  Boonyakorn Boonsri; Kiren Yacqub-Usman; Pakpoom Thintharua; Kyaw Zwar Myint; Thannicha Sae-Lao; Pam Collier; Chinnawut Suriyonplengsaeng; Noppadol Larbcharoensub; Brinda Balasubramanian; Simran Venkatraman; Isioma U Egbuniwe; Dhanwant Gomez; Abhik Mukherjee; Supeecha Kumkate; Tavan Janvilisri; Abed M Zaitoun; Thiti Kuakpaetoon; Rutaiwan Tohtong; Anna M Grabowska; David O Bates; Kanokpan Wongprasert
Journal:  Cancer Res Treat       Date:  2020-10-07       Impact factor: 4.679

7.  Downregulation of MCM8 expression restrains the malignant progression of cholangiocarcinoma.

Authors:  Jingcheng Hao; Haimin Deng; Yuan Yang; Lidan Chen; Qiang Wu; Pei Yao; Junen Li; Bowen Li; Xueli Jin; Haiqing Wang; Huaxin Duan
Journal:  Oncol Rep       Date:  2021-09-15       Impact factor: 3.906

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.